2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Plasma Cell Myeloma Refractory: new trials by email Literature Review of Plasma Cell Myeloma Refractory trials Research Report on Plasma Cell Myeloma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma SAR446523 - Plasma Cell Myeloma Refractory | Phase 1 | Recruiting | Sanofi | 87 | 2024-10-30 | 2026-03-25 |
| Isatuximab in Combination With Novel Agents in RRMM - Master Protocol Isatuximab, Dexamethasone, Pomalidomide - Plasma Cell Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Sanofi | 258 | 2021-01-25 | 2026-10-13 |
ALX148 (1) · Dexamethasone (1) · belantamab mafodotin (1) · belumosudil (1) · isatuximab (1) · pomalidomide (1)
Sanofi (2)
Australia (2) · France (2) · Israel (2) · Italy (2) · United States (2) · Canada (1) · Germany (1) · Greece (1) · Norway (1) · South Korea (1) · Spain (1)